NASDAQ:BPTS
Biophytis SA Stock News
$8.22
+0 (+0%)
At Close: May 20, 2024
Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity
01:20am, Tuesday, 14'th May 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the deve
Biophytis is Deploying its Partnership Strategy in Obesity
09:00am, Monday, 29'th Apr 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the de
Biophytis Announces Transfer of ADSs to OTC Market
05:30pm, Wednesday, 24'th Apr 2024
ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as
Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program
01:20am, Friday, 19'th Apr 2024
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speci
Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity
01:20am, Thursday, 18'th Apr 2024
IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company")
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
08:06am, Tuesday, 09'th Apr 2024
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1
Why Is Biophytis (BPTS) Stock Up 43% Today?
08:00am, Tuesday, 09'th Apr 2024
Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Tuesday after releasing its earnings results for the full year of 2023. Biophytis is still a clinical-stage biotechnology, which means it had
Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities
06:10pm, Monday, 08'th Apr 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company special
Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
05:30pm, Monday, 08'th Apr 2024
Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:
Results of the Combined General Meeting on April 2, 2024
05:20pm, Thursday, 04'th Apr 2024
All resolutions presented by the Company have been adopted PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA (NASDAQ:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis" or the
Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia
02:20am, Friday, 22'nd Mar 2024
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speciali
Biophytis Announces Receipt of Nasdaq Notice
05:15pm, Friday, 17'th Nov 2023
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speci
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the
Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel
05:15pm, Friday, 27'th Oct 2023
PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 27, 2023 / Biophytis SA (NASDAQCM:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the d
Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations
05:45pm, Wednesday, 27'th Sep 2023
Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopeni
